Patients with the cancers acute myelogenous leukemia (AML) and non-Hodgkins lymphoma (NHL) have dramatic differences in response to therapy and in progression and prognosis. By describing a dynamic model of the molecular and regulatory responses of these cancers, we will provide a means for predicting response to therapy based on an individual's genotype and molecular phenotype
Showing the most recent 10 out of 128 publications